Dr. Motzer on where pembrolizumab/lenvatinib fits in advanced RCC treatment paradigm

In an interview during the 2021 ASCO Annual Meeting Robert J. Motzer, MD, discussed where the combination of pembrolizumab (Keytruda) and lenvatinib (Lenvima) fits into the treatment paradigm for advanced renal cell carcinoma (RCC), based on findings from the phase 3 CLEAR trial. In the study the combination reduced the risk of death by 34% versus sunitinib (Sutent) in the frontline RCC setting. Motzer is the Kidney Cancer Section Head, Genitourinary Oncology Service; and Jack and Dorothy Byrne Chair in Clinical Oncology at Memorial Sloan Kettering Cancer Center.